TrovaGene, Inc. (TROV) financial statements (2021 and earlier)

Company profile

Business Address 11055 FLINTKOTE AVENUE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1091111111519
Cash and cash equivalents1091111111518
Short-term investments      0
Receivables0000000
Prepaid expense 111   
Other undisclosed current assets1   111
Total current assets:11101212131620
Noncurrent Assets
Operating lease, right-of-use asset122 
Property, plant and equipment1000122
Other noncurrent assets0000000
Other undisclosed noncurrent assets   2   
Total noncurrent assets:2222122
TOTAL ASSETS:13121415141822
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4332223
Accounts payable1010101
Accrued liabilities3322222
Debt111    
Deferred revenue and credits000
Other undisclosed current liabilities   1   
Total current liabilities:5443333
Noncurrent Liabilities
Long-term debt and lease obligation111    
Operating lease, liability111 
Liabilities, other than long-term debt0000111
Deferred revenue and credits111
Other liabilities0      
Derivative instruments and hedges, liabilities0000000
Other undisclosed noncurrent liabilities   2   
Total noncurrent liabilities:1112111
Total liabilities:6555444
Stockholders' equity
Stockholders' equity attributable to parent, including:77910101417
Preferred stock0000000
Common stock0000000
Additional paid in capital217212211208202202202
Accumulated deficit(209)(205)(201)(196)(192)(188)(184)
Other undisclosed stockholders' equity attributable to parent(1)(1)(1)(2)   
Total stockholders' equity:77910101417
TOTAL LIABILITIES AND EQUITY:13121415141822

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues0000000
Revenue, net0000
Sublease income 00 
Net investment income 00    
Cost of revenue     (0)(0)
Gross profit:000000(0)
Operating expenses(4)(4)(4)(4)(4)(4)(5)
Other undisclosed operating income     00
Operating loss:(4)(4)(4)(4)(4)(4)(4)
Nonoperating income (expense)0(0)0000(0)
Other nonoperating income (expense) (0)00 0(0)
Interest and debt expense    (0)(0)0
Net loss:(4)(4)(4)(4)(4)(4)(4)
Other undisclosed net income (loss) attributable to parent(0)000(0)01
Net loss attributable to parent:(4)(4)(4)(4)(4)(4)(4)
Preferred stock dividends and other adjustments(0)(0)(0)(0)(0)(0)(0)
Other undisclosed net loss available to common stockholders, basic   (0)  (3)
Net loss available to common stockholders, diluted:(4)(4)(4)(4)(4)(4)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(4)(4)(4)(4)(4)(4)(4)
Comprehensive loss:(4)(4)(4)(4)(4)(4)(4)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (3)01
Comprehensive loss, net of tax, attributable to parent:(4)(4)(4)(4)(7)(4)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: